JP2021535761A5 - - Google Patents

Info

Publication number
JP2021535761A5
JP2021535761A5 JP2021539337A JP2021539337A JP2021535761A5 JP 2021535761 A5 JP2021535761 A5 JP 2021535761A5 JP 2021539337 A JP2021539337 A JP 2021539337A JP 2021539337 A JP2021539337 A JP 2021539337A JP 2021535761 A5 JP2021535761 A5 JP 2021535761A5
Authority
JP
Japan
Prior art keywords
fusion protein
protein according
spd
domain
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021539337A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535761A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/050742 external-priority patent/WO2020056085A1/en
Publication of JP2021535761A publication Critical patent/JP2021535761A/ja
Publication of JP2021535761A5 publication Critical patent/JP2021535761A5/ja
Pending legal-status Critical Current

Links

JP2021539337A 2018-09-14 2019-09-12 sPD−1バリアント−Fc融合タンパク質 Pending JP2021535761A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862731488P 2018-09-14 2018-09-14
US62/731,488 2018-09-14
US201962888320P 2019-08-16 2019-08-16
US62/888,320 2019-08-16
PCT/US2019/050742 WO2020056085A1 (en) 2018-09-14 2019-09-12 Spd-1 variant - fc fusion proteins

Publications (2)

Publication Number Publication Date
JP2021535761A JP2021535761A (ja) 2021-12-23
JP2021535761A5 true JP2021535761A5 (cg-RX-API-DMAC7.html) 2022-09-07

Family

ID=68211179

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021539337A Pending JP2021535761A (ja) 2018-09-14 2019-09-12 sPD−1バリアント−Fc融合タンパク質

Country Status (11)

Country Link
US (2) US11498955B2 (cg-RX-API-DMAC7.html)
EP (1) EP3850003A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021535761A (cg-RX-API-DMAC7.html)
KR (1) KR20210058902A (cg-RX-API-DMAC7.html)
CN (1) CN112969710A (cg-RX-API-DMAC7.html)
AU (1) AU2019338416A1 (cg-RX-API-DMAC7.html)
CA (1) CA3109983A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ774126A (cg-RX-API-DMAC7.html)
SG (1) SG11202101904UA (cg-RX-API-DMAC7.html)
TW (2) TW202348622A (cg-RX-API-DMAC7.html)
WO (1) WO2020056085A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164428A1 (en) * 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
EP3991741A1 (en) * 2020-11-02 2022-05-04 Klinikum rechts der Isar der Technischen Universität München An immune checkpoint-modulating vsv-ndv hybrid virus for oncolytic virus immonotherapy of cancer
US20230414660A1 (en) * 2020-11-13 2023-12-28 Ludwig Institute For Cancer Research Ltd Pd-1 decoy variants for immunotherapy
WO2022137186A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
CN117321079A (zh) * 2021-01-11 2023-12-29 优特力克斯有限公司 包含抗4-1bb抗体及pd-1蛋白或其片段的双特异性表位结合蛋白及其用途
EP4288080A1 (en) * 2021-02-04 2023-12-13 Helsingin Yliopisto A cross-hybrid fc-fusion polypeptide targeting pd-l1 and methods and uses related thereto
WO2022187488A2 (en) * 2021-03-03 2022-09-09 Shattuck Labs, Inc. Mutant pd-1 extracellular domains
US20220387488A1 (en) 2021-05-12 2022-12-08 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies
EP4346875A4 (en) * 2021-05-28 2025-04-16 Akso Biopharmaceutical, Inc. BISPECIFIC FC FUSION PROTEINS WITH SPD-1 AND IL-15
KR20230044131A (ko) * 2021-09-24 2023-04-03 바이오엔시스템스 주식회사 Pd-1 및 il-15를 포함하는 융합단백질 이량체 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110034373A1 (en) * 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
CN103261217B (zh) * 2010-11-11 2017-04-26 港大科桥有限公司 可溶性 pd‑1变体、融合构建体及其用途
US20150368316A1 (en) * 2013-02-07 2015-12-24 Albert Einstein College Of Medicine Of Yeshiva University A selective high-affinity immune stimulatory reagent and uses thereof
WO2016023001A1 (en) 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
EP3177640B1 (en) * 2014-08-08 2020-05-06 The Board of Trustees of the Leland Stanford Junior University High affinity pd-1 agents and methods of use
WO2016164428A1 (en) * 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
US10844392B2 (en) * 2015-06-05 2020-11-24 Ibio, Inc. Materials and methods for producing endostatin fusion polypeptides in plant cells
PL3368572T5 (pl) * 2015-10-02 2026-07-20 Les Laboratoires Servier Przeciwciała anty-PD-1 oraz kompozycje
WO2017123548A1 (en) 2016-01-14 2017-07-20 Seattle Children's Hospital (dba Seattle Children's Research Institute) Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment
WO2018104473A1 (en) * 2016-12-07 2018-06-14 Oslo Universitetssykehus Hf Compositions and methods for cell therapy
WO2019241758A1 (en) * 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof

Similar Documents

Publication Publication Date Title
JP2022504550A5 (cg-RX-API-DMAC7.html)
JP2022115876A5 (cg-RX-API-DMAC7.html)
CN103554235B (zh) MERS-CoV病毒膜蛋白中的RBD片段及其编码基因和应用
JP2025184979A5 (cg-RX-API-DMAC7.html)
JP2014533518A5 (cg-RX-API-DMAC7.html)
RU2019139064A (ru) Композиции и способы для лечения цитомегаловируса
JP2013027391A5 (cg-RX-API-DMAC7.html)
JP2012152218A5 (cg-RX-API-DMAC7.html)
JP2017514522A5 (cg-RX-API-DMAC7.html)
CN114409770B (zh) 一种裂谷热病毒人源单克隆抗体及其应用
JP2024180560A5 (cg-RX-API-DMAC7.html)
JP2023522154A5 (cg-RX-API-DMAC7.html)
AU2016313660B2 (en) Polypeptide carrier for presenting target polypeptide and uses thereof
Wang et al. Expression, purification, and immunogenic characterization of Epstein–Barr virus recombinant EBNA1 protein in Pichia pastoris
JP2026075092A (ja) ワクシニアウイルスポリメラーゼ媒介性ウイルス複製
JP2025537544A5 (ja) 融合タンパク質及びそれを含む粒子状抗原
Bentz et al. KSHV LANA and EBV LMP1 induce the expression of UCH-L1 following viral transformation
JP2011530277A5 (cg-RX-API-DMAC7.html)
CN103333255A (zh) 一种长效hiv‐1膜融合抑制剂
RU2021110064A (ru) ГИБРИДНЫЕ БЕЛКИ ВАРИАНТА sPD-1—FC
Verheije et al. Redirecting coronavirus to a nonnative receptor through a virus-encoded targeting adapter
RU2546242C1 (ru) РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ ГЛАВНОГО КАПСИДНОГО БЕЛКА L1 ВИРУСА ПАПИЛЛОМЫ ЧЕЛОВЕКА ТИПА 18
JP2024516320A5 (cg-RX-API-DMAC7.html)
CN103243115A (zh) 一种诺如病毒多表位抗原基因
CN104561022B (zh) 家猪肿瘤坏死因子突变体的构建及蛋白表达纯化方法